Skip to content
CAR T-cell therapy episode artwork

Jan 3, 2019 12 min

CAR T-cell therapy

from Listen to The Lancet Oncology Hosted by The Lancet

Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

CAR T-cell therapy

0:00 12:44

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 12 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on January 3, 2019.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.